A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Clinical trial NCT03697629 · COMPLETED
Trial details
- NCT number
- NCT03697629
- Sponsor
- Canadian Myeloma Research Group
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-03
- Primary completion
- 2020-07-21
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.